Brief: Insilico Medicine Cayman Topco Expects H1 Net Profit $33.5 Million-$39.5 Million
09/07/2026 02:30
BRIEF-Insilico Medicine Cayman Topco Expects H1 Net Profit $33.5 Million-$39.5 Million July 9 (Reuters) - Insilico Medicine Cayman TopCo 3696.HK:
EXPECTS H1 2026 NET PROFIT OF USD33.5 MILLION-USD39.5 MILLION VERSUS NET LOSS YEAR AGO
EXPECTS H1 2026 REVENUE OF USD102.5 MILLION-USD106.5 MILLION, UP 272.7%-287.3% Y/Y
Further company coverage: 3696.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Insilico Medicine Cayman TopCo
See all newsInSilico Medicine jumps on progress in testing of new weight-loss drug
Development Collaboration
InSilico jumps on collaboration to develop biological frontier foundation models
HK-listed InSilico Medicine climbs as chairman buys shares
Brief: Insilico Medicine Cayman Topco's Chair Purchases Aggregate 113,500 Shares In Sept 4-7